Zent2U would like to announce to all our B2B business partners that the Rivaroxaban Oral Suspension dossier is ready and we are now able to offer the product for out-licensing in selected markets in Europe on an exclusive or semi-exclusive base. The dossier can also be adjusted to markets outside Europe based on request. ✍🏼
For more information and to discover the benefits of Rivaroxaban Oral Suspension please contact Tomas Pilarcik, Rahul Padhye, Clara Vitaller Baguena or Nina Fuentes de Tienda.
#thrombosis #b2b #zent2u #outlicensing
For more information and to discover the benefits of Rivaroxaban Oral Suspension please contact Tomas Pilarcik, Rahul Padhye, Clara Vitaller Baguena or Nina Fuentes de Tienda.
#thrombosis #b2b #zent2u #outlicensing
